Orthopaedic Surgery - Pigmented Villonodular Synovitis

Basics

Pigmented villonodular synovitis (PVNS) is an uncommon proliferative disorder of the synovium characterized by villous or nodular synovial overgrowth with prominent:

Hemosiderin deposition

Lipid-laden macrophages

and

Multinucleated giant cells.

The modern terminology places PVNS within the spectrum of tenosynovial giant cell tumor (TGCT), with classic intra-articular PVNS generally corresponding to:

Diffuse-type TGCT.

Localized nodular lesions are commonly classified as:

Localized-type TGCT.

Typical Appearance

Grossly, the involved synovium develops:

Yellow-brown or reddish-brown villous projections

or

Nodular masses.

The characteristic brown discoloration results largely from:

Repeated hemorrhage and hemosiderin accumulation.

Common Sites

The most frequently affected joint is the:

Knee.

Other important sites include:

Hip

Ankle

Shoulder

and other synovial joints.

Disease is almost always:

Unilateral.

Synonyms

Historical terms include:

Pigmented villonodular synovitis

Hemorrhagic villous synovitis

The broader modern term is:

Tenosynovial giant cell tumor.

Classification

PVNS/TGCT may occur in two principal patterns.

Localized Type

Localized disease forms a:

Discrete synovial nodule or mass.

It is generally easier to remove completely and has a lower recurrence risk.

Diffuse Type

Diffuse disease involves a broad area of:

Synovium

and may extend throughout the joint or into adjacent:

Bursae

Tendon sheaths

Extra-articular soft tissues.

Diffuse disease is more difficult to eradicate completely and has a higher recurrence rate.

Epidemiology

PVNS is:

Uncommon.

It most often presents in:

Young to middle-aged adults.

There is no strong sex predominance, although some series have reported a slight:

Female predominance.

Risk Factors

No well-established risk factors have been identified.

Recurrent:

Hemarthrosis

has historically been proposed as a contributing factor, but a causal relationship has not been proven.

Genetics

PVNS is now understood to have a neoplastic basis in many cases rather than being purely inflammatory.

A subset of lesions demonstrates molecular abnormalities involving:

CSF1 overexpression or rearrangement, which recruits large numbers of macrophages into the lesion.

There is no recognized inherited Mendelian predisposition in most patients.

Etiology

The precise initiating event is not completely understood.

Older theories proposed:

Chronic inflammation

Repeated hemorrhage

or

Reactive synovial proliferation.

Current evidence supports PVNS/TGCT as primarily a:

Locally aggressive neoplastic synovial process.

Experimental Hemarthrosis

Animal studies have historically produced PVNS-like changes after repeated joint bleeding.

However, these lesions may regress when hemorrhage stops, unlike the persistent and progressive behavior typical of human diffuse TGCT.

Associated Conditions

There are no consistent systemic disorders associated with PVNS.

Diagnosis

Diagnosis is based on:

Clinical presentation

Imaging, particularly MRI

and, when necessary,

Histopathologic confirmation.

Signs and Symptoms

Symptoms usually develop:

Insidiously

and progress slowly.

Common Symptoms

Patients may report:

Joint pain

Swelling

Stiffness

Reduced range of motion

Recurrent atraumatic effusions

Recurrent Effusion

A characteristic presentation is:

Repeated nontraumatic joint swelling.

The effusion may recur without a clear injury.

Warmth

The affected joint may feel:

Mildly warm

because of chronic synovial proliferation and inflammation.

Palpable Mass

A synovial mass may occasionally be palpable.

At the knee, a lesion may sometimes be detected in the:

Suprapatellar pouch

or along the joint margins.

Physical Examination

A complete joint examination should be performed.

For the knee, evaluate:

Effusion

Warmth

Tenderness

Range of motion

Ligament stability

Meniscal signs

Muscle bulk

Range of Motion

Motion may be reduced because of:

Pain

Effusion

Mechanical obstruction

Progressive synovial thickening

Muscle Atrophy

Chronic symptoms may lead to:

Quadriceps or other periarticular muscle atrophy.

Hip, Shoulder, and Ankle Disease

When deeper joints are involved, examination may be relatively nonspecific.

Possible findings include:

Reduced range of motion

Muscle wasting

Joint pain

without an easily palpable mass.

Laboratory Tests

Routine blood tests are usually:

Normal and nonspecific.

They may be obtained when infection or inflammatory arthritis is being considered.

Joint Aspiration

Aspiration may produce:

Reddish-brown or blood-stained synovial fluid.

This reflects:

Repeated intra-articular hemorrhage and hemosiderin deposition.

Persistent unexplained hemorrhagic effusions should raise suspicion for PVNS/TGCT.

Imaging

Plain Radiographs

Radiographs may be normal early in the disease.

Early Radiographic Findings

Possible findings include:

Soft-tissue swelling

Subtle pressure erosions

Small juxta-articular erosions

These erosions may occur in:

Non-weight-bearing portions of the joint.

Late Radiographic Findings

Longstanding disease may produce:

Erosions on both sides of the joint

Subchondral bone loss

Degenerative changes

and eventually

Joint-space narrowing.

Joint-space loss is typically a relatively late feature.

MRI

MRI is the most useful imaging modality for:

Establishing the diagnosis

Defining disease extent

Planning surgery

Detecting recurrence.

MRI Findings

Characteristic findings include:

Joint effusion

Lobulated or irregular synovial thickening

Nodular synovial masses

Low-signal hemosiderin deposits

Hemosiderin Signal

Hemosiderin produces:

Low signal intensity on both T1- and T2-weighted sequences, particularly on gradient-echo or susceptibility-sensitive sequences.

This may create:

Blooming or signal dropout.

This finding is highly characteristic of PVNS/TGCT.

Extra-Articular Extension

MRI is also useful for identifying extension into:

Posterior compartments

Bursae

Tendon sheaths

Adjacent soft tissues

This is especially important before surgery for diffuse disease.

Pathological Findings

PVNS may appear grossly as:

Diffuse villous proliferation

or

Discrete nodular masses.

Gross Appearance

The synovium is often:

Brown

Yellow-brown

or

Reddish-brown

because of extensive hemosiderin deposition.

Microscopic Findings

Histology typically demonstrates:

Mononuclear synovial-like cells

Multinucleated giant cells

Foamy histiocytes

Hemosiderin-laden macrophages

Inflammatory cells

Differential Diagnosis

Important alternative diagnoses include:

Inflammatory arthritis

Traumatic hemarthrosis

Septic arthritis

Synovial sarcoma

Hemophilic or other hemosiderotic arthropathy

Hemochromatosis

Synovial chondromatosis

Inflammatory Arthritis

Inflammatory arthropathies may cause:

Synovial thickening

Effusion

Pain

but typically lack the characteristic hemosiderin-rich MRI pattern of PVNS.

Infection

Septic arthritis should be considered when there is:

Acute pain

Fever

Marked warmth

Elevated inflammatory markers

Purulent aspirate

PVNS generally follows a more chronic course.

Synovial Sarcoma

Synovial sarcoma is an important malignant soft-tissue differential diagnosis, particularly when imaging shows:

An atypical extra-articular mass

Aggressive bone destruction

or unusual clinical features.

Hemosiderotic Arthropathy

Repeated hemarthrosis, such as in:

Hemophilia, can also produce hemosiderin deposition.

Clinical history and imaging distribution help distinguish it from PVNS/TGCT.

Treatment

General Principles

PVNS/TGCT is generally:

Benign but locally aggressive.

The principal goals are to:

Relieve symptoms

Remove abnormal synovium

Prevent recurrence

Preserve articular cartilage and joint function

Malignant Transformation

True malignant transformation is:

Extremely rare.

Most cases remain histologically benign despite potentially aggressive local behavior.

Symptomatic Treatment

Temporary symptom control may include:

Activity modification

Splinting or immobilization when necessary

NSAIDs

Analgesics

These measures do not eradicate the underlying proliferative synovial lesion.

Localized Disease

Localized nodular TGCT usually responds well to:

Complete excision

which can be performed:

Arthroscopically

or

Open, depending on location.

Diffuse Disease

Diffuse PVNS/TGCT usually requires:

Synovectomy.

Because disease may infiltrate multiple synovial recesses, complete removal can be difficult.

This contributes to a:

Higher recurrence rate.

Arthroscopic Synovectomy

Arthroscopic synovectomy through multiple portals is frequently used for:

Intra-articular diffuse disease, especially in the knee.

Advantages include:

Reduced soft-tissue trauma

Improved visualization of many compartments

Earlier postoperative rehabilitation

Open Synovectomy

Open surgery may be necessary when disease demonstrates:

Extensive posterior involvement

Extra-articular extension

Poor arthroscopic accessibility

At the knee, a posterior approach may be required for lesions involving the:

Posterior capsule or extra-articular tissues.

Combined Approaches

Some extensive diffuse lesions are treated with:

Combined arthroscopic and open synovectomy

or

Anterior and posterior open procedures

to improve disease clearance.

Radiotherapy

Radiotherapy may be considered in:

Recurrent

Residual

or

Diffuse disease that cannot be completely excised.

External-Beam Radiotherapy

External-beam radiation has historically been used for:

Difficult recurrent PVNS

or cases in which complete synovectomy would cause unacceptable morbidity.

Its use is individualized because of potential long-term radiation effects.

Radiosynovectomy

Intra-articular administration of radioactive isotopes has also been described as:

Radiation synovectomy.

It is used much less commonly and depends on regional practice and specialist expertise.

Systemic Targeted Therapy

For unresectable, recurrent, or highly morbid diffuse-type TGCT, modern treatment may include systemic agents targeting the:

CSF1/CSF1-receptor pathway.

These treatments are generally managed through:

Specialist musculoskeletal oncology teams.

Medication

NSAIDs and other analgesics may be used for:

Symptom control.

They do not alter the underlying disease.

Follow-Up

Because recurrence can occur after treatment, patients require clinical surveillance.

Follow-up may include:

Physical examination

and

MRI when recurrence is suspected or when diffuse disease has been treated.

Historical Surveillance

Older protocols commonly recommended MRI approximately every:

6–12 months

after treatment, particularly for diffuse disease.

Modern surveillance intervals are individualized according to:

Disease extent

Completeness of resection

Symptoms

Recurrence risk.

Prognosis

The overall prognosis is generally:

Good, particularly for localized disease.

The main concern is:

Local recurrence, especially after treatment of diffuse PVNS.

Localized Disease Prognosis

Complete excision usually provides:

Excellent symptom relief

with a relatively low recurrence risk.

Diffuse Disease Prognosis

Diffuse disease has a less predictable course because:

Complete synovectomy may be difficult

and recurrence is more common.

Repeated procedures may occasionally be necessary.

Complications

Recurrence

The most common complication is:

Local recurrence.

This is particularly important in:

Diffuse-type disease.

Articular Damage

Longstanding proliferative synovium may cause:

Cartilage destruction

Subchondral erosion

Bone loss

Secondary Arthritis

Chronic articular damage may ultimately result in:

Secondary osteoarthritis.

Joint Replacement

Severe end-stage joint destruction may eventually require:

Total joint arthroplasty, particularly in the hip or knee.

Surgical Complications

Treatment may also lead to:

Joint stiffness

Neurovascular injury

Infection

Postoperative fibrosis

depending on the extent and location of surgery.

Patient Monitoring

Follow-up should assess for:

Recurrent pain

Swelling

Effusion

Loss of motion

Palpable recurrent mass

MRI is especially useful for detecting:

Early local recurrence.

Asymptomatic Recurrence

Small asymptomatic recurrent lesions may occasionally be:

Observed, particularly when further treatment would produce greater morbidity than the disease itself.

Management should be individualized according to:

Symptoms

Growth

Joint damage

Disease location.

Key Principle

Pigmented villonodular synovitis, now generally classified within tenosynovial giant cell tumor, is a benign but locally aggressive proliferative synovial disorder characterized by hemosiderin deposition and recurrent atraumatic joint swelling.

MRI typically demonstrates:

Hemosiderin-related low signal with blooming or signal dropout.

Localized disease is usually treated successfully with:

Complete excision, whereas diffuse disease often requires:

Extensive synovectomy and careful long-term surveillance because recurrence is common.